These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3790633)

  • 21. Tardive dyskinesia and second-generation antipsychotics.
    Ross DE
    Am J Psychiatry; 2005 Feb; 162(2):405; author reply 405-6. PubMed ID: 15677620
    [No Abstract]   [Full Text] [Related]  

  • 22. Pisa syndrome: acute and tardive forms.
    Praharaj SK; Arora M
    South Med J; 2007 Aug; 100(8):853-4. PubMed ID: 17713320
    [No Abstract]   [Full Text] [Related]  

  • 23. [The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden].
    Povlsen UJ; Noring U; Meidahl B; Korsgaard S; Waehrens J; Gerlach J
    Ugeskr Laeger; 1987 Jun; 149(25):1682-5. PubMed ID: 3299955
    [No Abstract]   [Full Text] [Related]  

  • 24. Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
    Glazer WM
    J Clin Psychiatry; 2000; 61 Suppl 4():21-6. PubMed ID: 10739327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tardive dyskinesia syndrome in neuroleptic therapy. General considerations and clinical observations on forty cases investigated.
    Chiriţă V; Boişteanu P; Pirozynski T
    Rev Med Chir Soc Med Nat Iasi; 1987; 91(1):53-64. PubMed ID: 2889249
    [No Abstract]   [Full Text] [Related]  

  • 26. Exacerbation of tardive dyskinesia by Joseph disease.
    Browne JL; Hart RR
    J Clin Psychiatry; 1986 Jun; 47(6):315-6. PubMed ID: 3711030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tardive dyskinesia: are first signs reversible?
    Quitkin F; Rifkin A; Gochfeld L; Klein DF
    Am J Psychiatry; 1977 Jan; 134(1):84-7. PubMed ID: 12666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid.
    Naidu PS; Singh A; Kulkarni SK
    Psychopharmacology (Berl); 2003 Jun; 167(4):418-23. PubMed ID: 12669184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tardive dyskinesia in dopa-responsive dystonia: a reappraisal of the dopamine hypothesis of tardive dyskinesia.
    de la Fuente-Fernández R
    Neurology; 1998 Apr; 50(4):1134-5. PubMed ID: 9566407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of the incidence of tardive dyskinesias in 3 groups of patients treated with different neuroleptics].
    Barcia D; Pozo P; Ruiz ME; Forcadell F; Morcillo L; Soria JM; Carrasco E
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1987; 15(1):25-8. PubMed ID: 3577874
    [No Abstract]   [Full Text] [Related]  

  • 31. Experimental tardive dyskinesia.
    Bédard PJ; Boucher R; Larochelle L
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):551-4. PubMed ID: 6891821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
    Correll CU; Leucht S; Kane JM
    Am J Psychiatry; 2004 Mar; 161(3):414-25. PubMed ID: 14992963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
    Singh A; Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Basal ganglia iron in tardive dyskinesia: an MRI study.
    Elkashef AM; Egan MF; Frank JA; Hyde TM; Lewis BK; Wyatt RJ
    Biol Psychiatry; 1994 Jan; 35(1):16-21. PubMed ID: 8167198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride.
    Koch HJ; Szecsey A; Vogel M; Fischer-Barnicol D
    Int J Clin Pract; 2003 Mar; 57(2):147-9. PubMed ID: 12661802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early onset of severe dyskinesia following lithium-haloperidol treatment.
    Mann SC; Greenstein RA; Eilers R
    Am J Psychiatry; 1983 Oct; 140(10):1385-6. PubMed ID: 6624983
    [No Abstract]   [Full Text] [Related]  

  • 37. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia.
    Naidu PS; Singh A; Kulkarni SK
    Neuropharmacology; 2003 Jun; 44(8):1100-6. PubMed ID: 12763102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iron pigment in the brain of a man with tardive dyskinesia.
    Campbell WG; Raskind MA; Gordon T; Shaw CM
    Am J Psychiatry; 1985 Mar; 142(3):364-5. PubMed ID: 3970282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metoclopramide, an increasingly recognized cause of tardive dyskinesia.
    Kenney C; Hunter C; Davidson A; Jankovic J
    J Clin Pharmacol; 2008 Mar; 48(3):379-84. PubMed ID: 18223146
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.